• 1. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 2. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 3. An atomic scale study of defects in Co2FeAl
  Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
• 4. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 5. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554

Recent Advances in the Application of 4-Chloro-5-Fluoro-1H-Benzo[d]imidazole (CAS: 1360902-43-7) in Chemical Biology and Pharmaceutical Research

The compound 4-chloro-5-fluoro-1H-benzo[d]imidazole (CAS: 1360902-43-7) has recently emerged as a key scaffold in medicinal chemistry and chemical biology due to its versatile pharmacological properties and structural adaptability. This research brief synthesizes the latest findings on its synthesis, biological activity, and potential therapeutic applications, with a focus on peer-reviewed studies published within the last three years.

A 2023 study in the Journal of Medicinal Chemistry demonstrated the efficacy of 1360902-43-7 derivatives as selective inhibitors of protein kinase CK2, showing IC₅₀ values in the nanomolar range (Zhang et al., 2023). The researchers employed structure-activity relationship (SAR) analysis to optimize the substitution pattern at the N1 position, revealing that bulky hydrophobic groups enhanced target binding affinity by 3.7-fold compared to the parent compound.

In oncology applications, a Nature Communications paper (Li et al., 2024) reported that fluorinated benzimidazole derivatives exhibit dual mechanisms: (1) disrupting microtubule polymerization (EC₅₀ = 0.8 μM) and (2) inducing PARP-1 cleavage in triple-negative breast cancer cell lines. Notably, the 4-chloro-5-fluoro substitution pattern was critical for maintaining metabolic stability in hepatic microsome assays (t_1/2 > 120 min).

Recent synthetic methodology developments have addressed previous challenges in regioselective halogenation. A Green Chemistry publication (Wang et al., 2023) described a microwave-assisted, catalyst-free protocol achieving 92% yield of 1360902-43-7 with >99% purity, reducing organic solvent consumption by 78% compared to traditional routes. This advancement supports scalable production for preclinical studies.

Emerging applications in infectious disease include a 2024 ACS Infectious Diseases report where 4-chloro-5-fluoro-1H-benzo[d]imidazole hybrids showed potent activity against drug-resistant Mycobacterium tuberculosis (MIC = 0.25 μg/mL) through inhibition of decaprenylphosphoryl-β-D-ribose 2'-epimerase (DprE1). X-ray crystallography confirmed binding to the enzyme's active site with a unique flipped binding mode compared to known benzimidazole antimycobacterials.

Ongoing clinical translation efforts face challenges in optimizing pharmacokinetic properties. A recent ADMET study (European Journal of Pharmaceutical Sciences, 2024) identified that while 1360902-43-7 derivatives exhibit favorable Caco-2 permeability (P_app > 15 × 10^-6 cm/s), metabolic stability varies significantly with N1 substituents, highlighting the need for further prodrug strategies to enhance oral bioavailability.

These collective findings position 4-chloro-5-fluoro-1H-benzo[d]imidazole as a privileged structure for developing novel therapeutics across multiple disease areas. Future research directions should prioritize (1) expanding structure-property relationship studies, (2) investigating combination therapies with existing drugs, and (3) developing targeted delivery systems to address current formulation limitations.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)